Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 161Squamous Cell Carcinoma of Head and Neck 95Head and Neck Neoplasms 95Colonic Neoplasms 46Rectal Neoplasms 39Neoplasm Metastasis 35Carcinoma, Non-Small-Cell Lung 29Carcinoma, Squamous Cell 25Pancreatic Neoplasms 18Neoplasms 18Esophageal Neoplasms 18Lung Neoplasms 17Stomach Neoplasms 13Laryngeal Neoplasms 12Recurrence 11Oropharyngeal Neoplasms 11Mouth Neoplasms 11Esophageal Squamous Cell Carcinoma 11Colorectal Cancer Metastatic 10Tongue Neoplasms 9Carcinoma 9Breast Neoplasms 9Nasopharyngeal Carcinoma 8Hypopharyngeal Neoplasms 8Adenocarcinoma Of Esophagus 8Laryngeal Diseases 6Salivary Gland Neoplasms 5Neoplasms, Squamous Cell 5Glioblastoma 5Uterine Cervical Neoplasms 4

Interventions

Radiotherapy 2Radiosurgery 2Leucovorin 2Irinotecan 2Fluorouracil 2Drug Therapy 2sacubitril and valsartan sodium hydrate drug combination 1icotinib 1dostarlimab 1beta Carotene 1avelumab 1alpha-Tocopherol 1Varenicline 1Tyrosine Kinase Inhibitors 1Trastuzumab 1Tobacco Use Cessation Devices 1Therapeutics 1Thalidomide 1Temozolomide 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Semen Analysis 1Registries 1Probiotics 1Patient Reported Outcome Measures 1Panitumumab 1Nicotine Chewing Gum 1Myofascial Release Therapy 1Megestrol Acetate 1Isotretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Second Primary × Cetuximab × Clear all
NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Ludwig-Maximilians - University of Munich

Phase 2 Completed
57 enrolled
Tumor-Agnostic

Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡